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Application of neurotoxin- and pesticide-induced animal 
models of Parkinson’s disease in the evaluation of 
new drug delivery systems
Parkinson’s disease (PD) is the second most prevalent neuro-
degenerative disease after Alzheimer ś disease. It is charac-
terized by motor symptoms such as akinesia, bradykinesia, 
tremor, rigidity, and postural abnormalities, due to the loss 
of nigral dopaminergic neurons and a decrease in the dopa-
mine contents of the caudate-putamen structures. To this 
date, there is no cure for the disease and available treatments 
are aimed at controlling the symptoms. Therefore, there is 
an unmet need for new treatments for PD. In the past deca-
des, animal models of PD have been proven to be valuable 
tools in elucidating the nature of the pathogenic processes 
involved in the disease, and in designing new pharmaco-
logical approaches. Here, we review the use of neurotoxin- 
-induced and pesticide-induced animal models of PD, spe-
cifically those induced by rotenone, paraquat, maneb, MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and 
6-OHDA (6-hydroxydopamine), and their application in the 
development of new drug delivery systems for PD.
Keywords: Parkinson’s disease, rotenone, paraquat, maneb, 
MPTP, 6-OHDA, animal model, controlled drug delivery
INTRODUCTION
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder 
after Alzheimer ś disease. It is a chronic and progressive disease that mainly involves 
dopamine depletion in the central nervous system (CNS). It is characterized by the early 
death of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the accu-
mulation of Lewy bodies, which are abnormal intracellular aggregates containing pro-
teins, such as α-synuclein and ubiquitin (1, 2). This deficiency of dopamine in the basal 
ganglia causes movement disorders resulting in the typical symptoms of the disease, such 
as akinesia, bradykinesia, rigidity, resting tremor and postural abnormalities. Moreover, 
PD is also associated with several non-motor symptoms, such as olfactory dysfunction, 
cognitive impairment, psychiatric symptoms, sleep disorders, neurodegenerative dys-
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Diagnosis of the disease is currently based on medical history, physical and neurologi-
cal examination of the subject and the presence of certain symptoms. The latest advances in 
diagnosis (functional imaging, neuropsychological tests) can help the diagnosis based on a 
suspicion related to the clinical evaluation of the symptoms and signs present in the patient 
(4, 5). Currently, there are no biological markers that allow for a quick and accurate diagnosis 
of PD. For instance, the clinical criteria used by the UK Parkinson Disease Society Brain 
Bank, which are commonly used, have a diagnostic accuracy of only 80 % at the early stages 
of PD (6). Therefore, functional imaging is necessary to confirm the clinical diagnosis and 
understand the underlying pathophysiology. The definitive diagnosis is the presence of 
SNpc degeneration and Lewy pathology in the postmortem examination (7).
Treatment of PD is only symptomatic since there is no cure for the disease, with many 
of the drugs aiming to increase dopamine concentrations or directly stimulate dopamine 
receptors. The American Academy of Neurology recommends initiating one of the follow-
ing available drug therapies once the patient has developed symptoms of functional dis-
ability (8). Since dopamine does not cross the blood-brain barrier BBB and direct infusion 
into the brain is not possible in human subjects, the clinical management of PD is usually 
performed by means of the administration of dopamine agonists, the dopamine precursor 
L-DOPA, catechol-O-methyltransferase (COMT) inhibitors and monoamine oxidase B 
(MAO-B) inhibitors, N-methyl-D-aspartate (NMDA) receptor inhibitors, anticholinergics, 
alone or in combination. Dopaminergic therapy is highly effective in bradykinesia and 
stiffness in which dopamine and levodopa agonists help reduce disease progression and 
disability. Tremor responds to anticholinergic drugs such as trihexyphenidyl, but with a 
poor and inconsistent response to dopamine replacement therapy (9, 10).
With the need for new drugs and more effective treatments, several models have been 
developed to mimic features resembling those of human PD in experimental animals, and in 
order to design and evaluate drug molecules that favor neuroprotection and decrease neuro-
nal cell death as occurs in PD. In this work, we present a review of the main experimental 
models of PD based on the use of pesticides or neurotoxins, and their relevance for the study 
and knowledge of the disease, with a special focus on the application of these experimental 
models in the development of controlled drug delivery systems for the treatment of PD.
In recent years, new drug delivery systems are being developed to improve the effi-
cacy of the pharmacological treatments of PD. In this regard, the design of controlled deli-
very systems is of great interest as they can maintain constant drug levels for prolonged 
periods of time, which allows reducing the frequency of administration and improve 
 patient compliance, among other benefits. They can be either biodegradable or non-biode-
gradable depending upon the nature of the polymer or material used for their fabrication. 
Among controlled drug delivery systems, the hydrogels and polymeric or lipid micropar-
ticles (MPs) and nanoparticles (NPs) seem to be the most effective in providing neuropro-
tection and facilitating the delivery of drugs and small molecules to the brain. E.g., lipid-
based nanocarriers are very interesting for the development of nanosystems destined to 
reach the CNS after intranasal administration.
MODELS BASED ON PESTICIDES
Pesticides are substances of natural or synthetic origin used to exterminate, prevent, 
and control any unwanted pest or organism and can be classified as insecticides, herbici-
des and fungicides (11). In the late 1980s, several epidemiological studies found an  increased 
37
Y. Casanova et al.: Application of neurotoxin- and pesticide-induced animal models of Parkinson’s disease in the evaluation of new drug 
delivery systems, Acta Pharm. 72 (2022) 35–58.
 
risk of developing PD in populations exposed to pesticides, herbicides and industrial 
 compounds (12). A recent study performed by Belvisi et al. (13) indicated that in five out of 
eight studies reviewed (14–18) greater risk of developing PD was associated with such 
substances but in the other three studies (19–21) no significant association was found 
 between occupational exposure to pesticides and PD. These opposite results could be 
 explained by the cohort sizes and follow-up duration of the different studies which were 
not comparable. Therefore, correlations between agrochemical exposure in populations 
and increased risk of developing PD have been difficult to conclude due to a lack of details 
on exposure to particular agents. Nevertheless, the emphasis has been made on rotenone, 
paraquat and maneb, as possible environmental causes of PD.
Rotenone
Rotenone (RT) is an organic pesticide extracted from the roots of some tropical plants 
of the genera Lonchocarpus and Derris. Chemically it is the (2R,6aS,12aS)-1,2,6,6a,12,12a-
hexahydro-2-isopropenyl-8,9-dimethoxychromeno[3,4-b]furo(2,3H)chromen-6-one (Table I). 
Due to its high liposolubility, it can pass through biological barriers and cell membranes 
(22). RT was firstly used as a causative agent of PD in 1985 when Heikkila et al. (23) injected 
this mitochondrial complex I inhibitor directly into the brain of rats. They demonstrated 
that at a concentration of 5 mmol L–1, approximately five hundred thousand times greater 
than its maximal inhibitory concentration (CI50), RT was able to eliminate dopaminergic 
neurons. This contribution opened a new field of research since PD was related to sys-
temic mitochondrial defects. In this respect, various research groups began to work with 
the systemic administration of mitochondrial toxins such as rotenone to investigate PD. 
Ferrante et al. (24), reported that the administration of rotenone (10–18 mg kg–1 per day) 
produced non-specific brain lesions and peripheral toxicity in rats. Betarbet et al. (25) demon-
strated that the administration of RT (2–3 mg kg–1 per day) to rats for 33 days caused selec-
tive nigrostriatal dopaminergic degeneration which could be associated behaviorally with 
hypokinesia and rigidity. They also found fibrillar cytoplasmic inclusions containing ubi-
quitin and α-synuclein proteins in nigral neurons of RT treated rats.
It was also reported that systemic administration of RT may reproduce other features 
of PD in experimental animal models such as the alterations of the retina, loss of testoster-
one and sleep disorders (26–28). Other studies performed in mice have demonstrated that 
the selective toxicity of RT can be related to inhibition of the NADH gene dehydrogenase 
ubiquinone proteins Fe-S4 (NDUFS4) which encode the mitochondrial complex I which is 
inhibited by RT. Other underlying mechanisms have also been reported for RT, such as 
depolymerization of microtubules and accumulation of reactive oxygen species (ROS) in 
mesencephalon cultures (29).
In summary, the RT model is one of the most frequently used models for inducing 
parkinsonian symptoms in experimental animals due to the following characteristics:
(i) RT model reproduces most of the motor disorders and histopathological features of 
PD, including Lewy bodies and some conditions associated with α-synuclein (α-Syn) accu-
mulation (30, 22),
(ii) RT and other pesticides are potent mitochondrial inhibitors associated with a high 
incidence of sporadic PD in humans mainly in rural/agricultural areas,
(iii) RT is a lipophilic compound and, as such, can pass through biological barriers 
without relying on transporters (22).
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However, RT has some drawbacks such as high photoreactivity and systemic (cardio-
vascular) toxicity which leads to significant mortality rates (~30 % of the animals), regard-
less of the administration route (25). This toxicity makes it necessary to use a large number 
of animals to assure the statistical significance of the results obtained when performing 
behavioral, biochemical and histological analysis. Moreover, due to its low water solubi lity 
selection of the appropriate vehicle and the administration route is more complex (31). 
Another drawback, as indicated previously, is that RT also causes non-PD-related symp-
toms such as cardiovascular effects (32).
RT is usually dissolved in polar vehicles with the incorporation of surfactant agents 
such as carboxymethyl cellulose (CMC) or naturally occurring oils (sunflower, castor oil). 
The incorporation of dimethylsulfoxide (DMSO) can minimize the use of surfactants or 
even prevent it (33). Regarding the route of administration, RT can be given either subcu-
taneously, intraperitoneally, orally or intracerebrally with the selection of the dose de-
pending on the administration route and the type of treatment chosen (acute or chronic) 
(34).
Controlled-release systems using the rotenone model. – Some of the new controlled-release 
systems have been recently evaluated in RT-induced animal models of PD. For example, 
rasagiline mesylate (RM) is a potent, selective and non-reversible MAO-B inhibitor that 
exhibits neuroprotective effects and it’s currently used as monotherapy in early PD. How-
ever, due to its short elimination half-life (1.5–3.5 h), RM must be given orally in daily 
doses. Kanwar et al. (35) encapsulated RM in polycaprolactone microspheres (MPs) in order 
to expand the dosing intervals, taking into consideration that patients with PD develop 
dysphagia, i.e. difficulty in swallowing. The new formulation was evaluated in Sprague- 
-Dawley rats after stereotaxic administration of RT [6 mg in 2 mL DMSO:PEG (1:1)]. The 
administration of the RM-loaded formulation improved several behavioral (locomotor 
 activity, grip strength) and biochemical (lipid peroxidation, reduced glutathione, etc.) para-
meters. Non-significant differences were found between the daily administration of RM 
in solution and the polymeric MPs given once a month, which makes this approach very 
interesting for treating PD patients with dysphagia. Fernandez et al. (36) also developed a 
new formulation consisting of RM-loaded MPs using poly(lactic-co-glycolic) acid (PLGA) 
as a biodegradable polymer. The system was assayed in the RT model of PD induced in 
Wistar rats. Daily i.p. doses of RT (2 mg kg–1) induced neuronal and behavioral changes 
similar to those occurring in PD. Once an advanced stage of PD was achieved, animals 
received RM in saline (1 mg kg–1 per day) or encapsulated within PLGA MPs (amount of 
microspheres equivalent to 15 mg kg–1 RM given on days 15 and 30). After 45 days, RM 
showed a robust effect on all analytical outcomes (brain histology, immunochemistry, 
 behavioral testing) with non-statistically significant differences found between the admini-
stration of RM in solution or encapsulated within polymeric MPs.
Many of the experimental applications of the RT model found in the literature are 
related to the evaluation of dopaminergic agonists, a therapeutic strategy to provide con-
tinuous dopamine (DA) receptor stimulation. Most DA agonists show low bioavailability 
due to extensive first-pass metabolisms after oral administration, thereby implying the 
need for the daily administration of various doses. This fact makes them good candidates 
for the development of controlled delivery systems. With this aim, Barcia et al. (37) deve-
loped ropinirole (RP) PLGA nanoparticles (NPs) to improve the access of RP to the CNS. 
The RT model was induced in Wistar rats at a dose of 2 mg kg–1 per day given i.p. Once 
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neurodegeneration was established (15 days), animals received RP in saline (1 mg kg–1 per 
day for 35 days) or RP-loaded PLGA NPs (amount of NPs equivalent to 1 mg kg–1 per day, 
every 3 days for 35 days). Brain histology and immunochemistry Nissl-staining, glial fibri-
llary acidic protein (GFAP) and tyrosine hydroxylase (TH) immunohistochemistry, and 
behavioral testing (catalepsy, akinesia, rotarod and swim test) showed that RP NPs were 
able to revert PD like symptoms of neurodegeneration in the RT-induced model.
Negro et al. (38) developed RP-loaded PLGA MPs and assayed the formulation in the 
RT model induced in Wistar rats. After 15 days of daily i.p. doses of RT (2 mg kg–1), animals 
received RP in saline (1 mg kg–1 per day for 45 days) or RP-loaded PLGA MPs at two dose 
levels (amount of MPs equivalent to 7.5 or 15 mg kg–1 RP given on days 15 and 30). All the 
outcomes analyzed (brain histology, immunochemistry, and behavioral testing) showed 
that animals receiving RP either daily in solution or every two weeks encapsulated within 
the MPs reverted the PD symptoms, with the best results obtained in animals receiving 
the RP microspheres at the highest dose level.
Patel et al. (39) have developed nanocarriers (microemulsions, ME) of RP for transder-
mal application which are considered highly efficient as colloidal soft nanocarriers in dermal 
and transdermal drug delivery systems. In this study and in order to achieve sustained and 
controlled permeation of RP through the skin, ME was converted into a ME-based gel (MEG) 
using a biocompatible gelling agent. The system was assayed in Sprague-Dawley rats after 
s.c. administration of RT (2 mg kg–1 per day) for 11 days. Chronic administration of RT caused 
the destruction of dopaminergic neurons resulting in motor dysfunctions (rigidity, slower 
movement, and inability to move). Administration of the MEG developed for RP (2.16 
mg kg–1 per day via transdermal route) improved the motor function by 76 %, whereas the 
marketed tablet suspension of RP (2.16 mg kg–1 per day via oral route) showed only 5 % resto-
ration of the normal function. Moreover, the new transdermal delivery system successfully 
restored the catalase and superoxide dismutase levels which were significantly reduced by 
RT administration.
Resveratrol (RSV) has recently drawn attention since it is considered a red wine- 
- derived polyphenol with cardioprotective and neuroprotective effects. In this regard, 
Palle and Neerati (40) developed RSV-loaded nanoparticles (NPs) by temperature- 
- controlled antisolvent precipitation. The new therapeutic system was evaluated for its 
neuroprotective effects in the RT-induced model in Wistar rats. For this, the administration 
of RT (2 mg kg–1, s.c.) for 35 days produced motor deficits, decreased rearing behavior, 
mitochondrial dysfunction, and oxidative stress in the animals. Oral administration for 35 
days of RSV-loaded NPs (40 mg kg–1) 30 min before the administration of RT showed better 
efficacy than the oral administration of RSV in solution (40 mg kg–1) in attenuating the 
 RT-induced behavioral, biochemical and histological alterations observed in the animals.
Accumulation of α-Syn protein, mitochondrial dysfunction, oxidative stress, and neuro-
nal cell death are among the main pathological hallmarks of PD. In this regard, the 
 combination of piperine and curcumin may have potential interest due to their beneficial 
cognitive and antioxidant properties. However, the access of drugs to the brain is limited 
by the BBB. To overcome this passage, Kundu et al. (41), designed a new delivery system 
consisting of dual drug curcumin and piperine co-loaded glyceryl monooleate NPs 
(CPNPs) coated with various surfactants to improve their passage to the brain. The new 
system was evaluated in the RT-induced mouse model of PD after oral administration of 
RT (30 mg kg–1) for 28 days. CPNPs were given orally at an equivalent dose of 200 mg kg–1 
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every alternate day, 30 min before the administration of RT. The results obtained showed 
that the new formulation was able to cross the BBB, rescue the RT-induced motor coordina-
tion impairment, and restrained dopaminergic neuronal degeneration in the PD animal 
model.
The sapogenin (camelliagenin) isolated from Camellia oleifera seeds has demonstrated 
antioxidative, anti-inflammatory and analgesic activities which could be related to its neuro-
protective effects. In this regard, Yang et al. (42) synthesized iron-sapogenin NPs. The 
 neuroprotective effects of the formulation were evaluated in RT-induced neurodegenera-
tion in Kunming mice injected s.c. with RT (50 mg kg–1 per day) for 6 weeks and treated by 
i.v. injection of the iron-sapogenin complex at three dose levels (25, 50 and 100 mg kg–1 for 
7 days). Behavioral disorders were attenuated by the delivery system and increased super-
oxide dismutase activity, tyrosine hydroxylase expression, dopamine and acetylcholine 
levels in the brain were increased in a dose-dependent manner. Iron-sapogenin NPs 
showed significantly better effects than the sapogenin alone.
The occurrence of ocular manifestations in many neurodegenerative diseases, includ-
ing PD, emphasizes the strong connection between the brain and the retina. PD patients 
often suffer from visual symptoms such as reduced visual acuity, low contrast sensitivity, 
and disturbed color vision. Normando et al. (43) used the RT-induced rodent model of PD 
to investigate retinal manifestations in PD. In this study, RT was injected i.p. to Dark  Agouti 
rats at a dose of 2.5 mg kg–1 per day for 60 days. The retinal evaluation was assessed by 
optical coherence tomography (OCT), and by longitudinal in vivo imaging with detection 
of apoptosing retinal cells (DARC). The results obtained showed increased apoptosis of 
retinal ganglion cells with a transient swelling of the retinal layers after 20 days of initiat-
ing RT. By day 60, histological neurodegenerative changes in the substantia nigra and stria-
tum were observed suggesting that retinal changes precede the “traditional” pathological 
manifestations of PD. The efficacy of a novel rosiglitazone (RG) liposomal formulation was 
evaluated in this PD model. For this, RT was administered for 10 days, followed by a single 
i.p. injection of liposome-encapsulated rosiglitazone (1 or 1.4 mL kg–1). Administration of 
this new liposomal formulation resulted in greater neuroprotective effects both in the 
retina (day 20) and brain (day 60) than daily administration of the free drug. Moreover, 
DARC and OCT measures in the retina were good predictors of therapeutic efficacy in the 
brain.
Paraquat
Paraquat (PQ) (1,1’-dimethyl-4,4’-bipyridyl dichloride) is a quaternary nitrogen herbi-
cide (Table I) frequently used in agriculture for broadleaf weed control due to its low cost, 
rapid action and a broad spectrum of activity (44). It was first introduced to the market in 
the ’60s; however, its use is currently banned in many countries, including the 27 countries 
of the European Union, due to its toxicity on plants, animals and humans.
A study performed in 1985 by Barbeau et al. (45) showed that PQ caused a significant 
reduction in dopamine concentrations resulting in behavioral changes similar to those 
induced by MPP+ (1-methyl-4-phenylpyridinium). The pathophysiological mechanism of 
PQ resembles that of the MPP+ cation since PQ as a divalent cation (PQ++) can undergo the 
redox pathway in microglia, resulting in a monovalent cation (PQ+) accompanied by the 
production of superoxide that results in oxidative stress and cytotoxicity. PQ+ is also 
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 recognized by the dopamine transporter (DAT) causing accumulation in dopaminergic 
neurons which in turn generates superoxide and reactive dopamine species leading to 
dopaminergic neurotoxicity (46).
PQ can cross the BBB affecting the dopaminergic system as is transported into dopa-
minergic neurons via the dopamine transporter (47). Systemic administration of PQ in 
C57BL/6 mice resulted in a reduction of dopaminergic neurons, degeneration of the dopa-
minergic fibers of the striatum and a decrease in ambulatory activity, with the neurotoxi-
city exerted by PQ associated with its ability to induce the formation of free radicals, facili-
tate fibrillation of α-synuclein and cause cell death by apoptosis. Other studies also showed 
that PQ produces an increase in reactive oxygen species level, aggregations of α-synuclein, 
the formation of Lewy bodies and neuroselective lesions in the SNpc, features resembling 
those encountered in human PD (46, 48). PQ also activates other molecular signaling path-
ways including an increase in NADPH oxidase expression, depletion of oxidized glutathi-
one, and Jun N-terminal kinase (JNK) activation (49).
Table I. Chemical structure and mechanism of action of pesticides and neurotoxins used in animal models of 
Parkinson´s disease
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Different studies have confirmed the ability of PQ to destroy nigral dopaminergic 
neurons in animal models (mice, rats) (50, 51). One important feature of PQ toxicity is that 
it exhibits high selectivity for SNpc dopaminergic neurons which in turn results in almost 
50 % loss after multiple injections (52). It has also been demonstrated the relationship bet-
ween age and PQ neurotoxicity as older animals (mice, rats) exhibit enhanced vulnerabi-
lity to this pesticide (53). However, doubts have been raised in recent studies regarding the 
effects of systematic PQ administration since it does not produce dopamine depletion in 
the striatum or evident motor deficits (54).
Currently, PD models induced with PQ are mainly developed either with the divalent 
cation (PQ++) or the stable form (PQ+). PQ++ is not transported via DAT but is converted to 
PQ+ through redox cycling (55).
In most of the studies that evaluate the neurotoxicity of PQ, the agent is administered 
by i.p. once weekly for several weeks. One particular feature of the PQ model is that it can 
be used alone or in combination with other agents such as maneb, as concurrent exposure 
to both chemicals in adult mice has resulted in marked DA fiber loss, altered DA turnover 
and decreased locomotor activity (56, 57).
Controlled-release systems using paraquat model. – Srivastav et al. (58) have recently syn-
thesized biocompatible piperine-coated gold nanoparticles (AuNPspiperine) to specifi-
cally target PQ-induced metabolic complications both in Drosophila melanogaster and SH- 
-SY5Y (human neuroblastoma) cells. Piperine, a natural alkaloid found in Piper longum and 
Piper nigrum, exerts potential antiparkinsonian activity due to its anti-inflammatory and 
antioxidative properties (59) also being able to counter motor dysfunctions and dopamine 
depletion (60). The authors found that in the in vitro model tested AuNPspiperine were able 
to maintain the mitochondrial membrane potential thereby protecting the cells against 
PQ-induced toxicity. Moreover, in PQ-treated flies, the new controlled delivery system was 
able to suppress oxidative stress and mitochondrial dysfunction leading to inhibition of 
apoptotic cell death. AuNPspiperine also improved locomotor function and life span in PQ 
exposed flies.
Maneb
Maneb (MB) is a fungicide in the form of a polymeric complex of manganese with 
anionic ligand ethylene-bis(dithiocarbamate) (Table I). It is used either as a contact pesti-
cide to treat seeds or for direct application to emerging soil crops. MB exacerbates the 
toxicity of other agents such as PQ in mouse models, just as other dithiocarbamates disrupt 
the function of the ubiquitin-proteasome system, a system that is believed to be involved 
in genetic and idiopathic forms of PD (11).
In vitro studies have shown that the neurotoxicity exerted by MB is related to inhibi-
tion of the enzymatic activity of mitochondrial complex III and oxidation of catechol-
amines. Moreover, systemic administration of both PQ and MB can induce a synergistic 
decrease of DA in the striatum, degeneration of SNpc and motor dysfunction (57).
Berry et al. (48), in a literature review, indicated that the study performed by Thiru-
chelvam et al. (57), in C57BL/6 male mice injected i.p. with PQ (0.3 mg kg–1) or MB (1 mg kg–1), 
showed that exposure to these pesticides during the postnatal period produced permanent 
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and progressive alterations in the nigrostriatal DA system, that could be involved in the 
induction of neurodegenerative disorders.
MB is also able to potentiate both the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine) and the PQ effects (56, 61). In rodents, the combination of PQ and MB can elicit dopa-
mine depletion in the striatum, selective dopaminergic cell loss, accumulation of α-synuclein 
and PD-like motor and non-motor symptoms. Moreover, a synergistic effect has been 
 demonstrated after the administration of PQ (10 mg kg–1) and MB (30 mg kg–1) to mice twice 
a week for 6 weeks, a dosage regimen in which exacerbated parkinsonism was observed 
when compared to the administration of each compound alone (56).
However, with the use of MB as occurs with RT, the animal model has led to contra-
dictory results, variable loss of striatal DA content and cell death (62). Therefore, research 
efforts are still needed to elicit the exact mechanisms by which PQ induces neurodegene-
ration.
To date, no articles have been found in the literature regarding the evaluation of con-
trolled-release systems in MB-induced animal models of PD.
MODELS BASED ON NEUROTOXINS
Neurotoxin models remain the most popular models in PD animal studies with MPTP 
and 6-OHDA being the most frequently used. However, they lack the ability to mimic the 
pathological features of PD, as they only mimic the symptoms. These models only resemble 
the symptoms and motor dysfunctions occurring once severe dopamine depletion is 
reached (63).
MPTP
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Table I) was first described as 
an agent causing parkinsonism in 1982, in California, when a group of drug addicts develo-
ped a severe acute stiffness syndrome which improved upon receiving levodopa and 
 dopamine agonists (64).
Due to its lipophilicity, MPTP readily crosses the BBB. When in contact with mono-
amine oxidase B it transforms into 1-methyl-4-phenylpyridinium (MPP+), which is the 
 active compound that enters the dopamine neurons of the SNPc. Once inside, it blocks 
complex I of the mitochondrial electron transport chain causing a decrease in adenosine 
triphosphate (ATP) and accumulation of ROS, which in turn results in cell death (65). 
MPTP causes damage to the dopaminergic pathway which is easily reproducible in animal 
models. Moreover, when infused over a period of 30 days, it can induce the formation of 
ubiquitin and α-synuclein inclusions resembling the features of human PD (66).
It has also been postulated that the toxicity of MPTP through the MPP+ entity may be 
dependent on the neuromelanin content since the affinity of MPP+ for neuromelanin is 
very high (24) and MPP+ can remain in the cytosol interacting with enzymes (67).
Induction of parkinsonian syndromes with MPTP is usually performed in rodents, 
dogs, cats and non-human primates. The effects of MPTP in mice vary with age, dose, 
route of administration and number and frequency of injections. It has been demonstrated 
47
Y. Casanova et al.: Application of neurotoxin- and pesticide-induced animal models of Parkinson’s disease in the evaluation of new drug 
delivery systems, Acta Pharm. 72 (2022) 35–58.
 
that the damage caused by MPTP at the mitochondrial level increases with age as brains 
of older mice accumulate more MPP+ than those of younger animals, which may contribute 
to greater sensitivity to MPTP toxicity.
Of the numerous studies performed with MPTP in mice, some have been based on the 
s.c. or i.p. administration of 10–30 mg kg–1 per day for several days, depending on whether 
an acute or chronic model is being developed. For instance, for the acute model doses of 
MPTP ranging between 20–30 mg kg–1 given the same day have been described, whereas, 
for the chronic model, two dosage regimens have been described: administration of daily 
doses of 30 mg kg–1 for five consecutive days or daily doses of 4 mg kg–1 for 20 days (68, 69).
The MPTP mouse model has some advantages over the one induced by 6-OHDA 
(6-hydroxydopamine) due to the fact that it does not require stereotaxic surgery for its 
administration, Moreover, it is also able to develop bilateral degeneration of the nigro-
striatal tract resembling that found in human PD, and also mimic other known biochemical 
features such as decrease in striatal levels of DA and TH (tyrosine hydroxylase), increase 
of both striatal precursor protein preproenkephalin-A (PPE-A) and acetylcholine (ACh) 
levels, increase of extracellular glutamate levels and reduction of glutathione (GSH) in 
basal ganglia (70). The MPTP mouse model does, however, have some disadvantages over 
the 6-OHDA model, especially regarding reproducibility and the range of behavioral out-
comes that can be obtained. Moreover, mice are less sensitive to MPTP than primates, 
therefore, requiring higher doses that can be lethal, due to the resulting peripheral neuro- 
or cardiotoxicity (71).
All primate species in which MPTP has been tested are sensitive to this neurotoxin, 
including squirrel, monkeys, baboons, macaques, marmosets and vervet monkeys. Repe-
ated systemic administration of MPTP by i.p., s.c., i.v. or i.m. injections, with varying doses 
depending on species and route, are able to rapidly develop motor alterations resembling 
those found on human PD, such as bradykinesia, postural instability and rigidity (72), as 
well as non-motor symptoms such as cognitive deficits (73) and temporary autonomic 
 disturbances (74).
Controlled-release systems using the MPTP model. – Glial cell line-derived neurotrophic 
factor (GDNF) is a potent neuroprotective agent currently considered as a promising can-
didate for the treatment of PD, due to its potent trophic effect on the dopaminergic system. 
However, GDNF is not able to cross the BBB and has a relatively short elimination half-life. 
For this, attempts have been made by Garbayo et al. (75) to design new controlled delivery 
systems to increase the stability and retention of neurotrophic factors such as GDNF aim-
ing to improve the treatment of PD. In this study, GDNF-loaded microparticles were pre-
pared by the solvent extraction-evaporation method using PLGA 503H as polymer. The 
new formulation was applied to Macaca fascicularis non-human primates that received 
weekly i.v. doses of MPTP (0.5 mg kg–1) until the animals reached stable severe parkinso-
nian symptoms. Administration of the new drug delivery system was performed by stereo-
taxic surgery. The results obtained showed that a single administration of microencapsu-
lated GDNF (25 mg) within the putamen achieved sustained levels of the neurotrophic 
factor in the brain, which were able to improve both motor and dopaminergic function. 
Moreover, in the SNpc GDNF was able to increase the number of dopaminergic neurons, 
regardless of the severity of neurodegeneration.
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6-OHDA
6-Hydroxydopamine (6-OHDA) (Table I) is another neurotoxin widely used to induce 
parkinsonism in experimental animal models. It is a highly oxidizable DA analog that can 
be captured by the dopamine transporter, which in turn results in selective damage of 
dopaminergic neurons in the SNpc (76).
6-OHDA does not cross the BBB, therefore, making it necessary to perform its direct 
administration into the brain parenchyma. This represents one of the main drawbacks as 
specialized stereotaxic surgical instruments and training is required for its administra-
tion. Regarding the cytotoxicity exerted by 6-OHDA three mechanisms have been pro-
posed: intra-extracellular self-oxidation of 6-OHDA resulting in the formation of hydroxyl, 
hydrogen peroxide and superoxide radicals, the appearance of hydrogen peroxide due to 
the monoamine oxidase, and inhibition of mitochondrial electron transport chain com-
plexes I and IV [NADH dehydrogenase (complex I) and cytochrome c oxidase (complex 
IV)]. It is postulated that these events resemble those occurring in the PD brain, which 
supports the interest and validity of the 6-OHDA model. Moreover, as a result of these, 
ROS are produced, which in turn explains the oxidative stress leading to the cytotoxic 
 effect of 6-OHDA. Recent studies have demonstrated that the administration of 6 μg of 
6-OHDA in the dorsal striatum of rats is able to produce an increase in the oxidation level 
of proteins and lipoperoxidation products as a function of time (77), which could be due 
to mitochondrial oxidative stress leading to both neuroinflammation and cell death by 
apoptosis (78).
When trying to understand the in vivo effects and neurodegenerative mechanisms of 
6-OHDA, injection of the neurotoxin can be performed into the medial forebrain bundle 
(79), the substantia nigra (80), or at the intrastriatal site (81–83). Bilateral lesions of the 
 ascending forebrain dopaminergic system have been reported to induce severe aphagia, 
adipsia and akinesia, with the need for tube feeding of the animals (84). Intranigral lesions 
usually cause pain and massive degeneration of the injured nucleus, which hinders their 
use when evaluating the mechanisms involved in neurotoxicity and death, as a conse-
quence of long-term oxidative stress.
On the other hand, the intrastriatal lesion model produces a progressive loss of dopa-
minergic neurons in the SNpc, resembling the nigrostriatal lesions found in PD after uni-
lateral intracranial injection (85, 86) and bilateral injection (87). In the late ’90s, Kirik et al. 
(88) established the optimal parameters when causing unilateral ventrolateral striatum 
 lesions after injecting a 6-μg dose of 6-OHDA at three different striatum sites. The results 
obtained indicated that the effect of the intrastriatal injection depends on the site of injury 
and the dose given. In this study, 80 % reduction in striatal innervation and almost 90 % 
loss of the nigral dopaminergic neurons was observed.
The 6-OHDA model does not reproduce the presence of Lewy bodies (89). To over-
come this drawback, α-Syn murine models have been developed, based on knockout 
 models (90), gene expression models (91), or intracerebral injection of α-Syn (92). Although 
further research is needed, this is an interesting approach since this protein is a key com-
ponent of Lewy bodies.
Since the 6-OHDA model reproduces several of the cellular alterations occurring in 
PD, it is a valuable model to study the cytotoxicity mechanisms involved and the cellular 
processes activated by oxidative stress (neuroinflammation and neuronal death).
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Controlled-release systems using the 6-OHDA model. – When trying to increase the DA 
levels at the CNS, a novel approach is based on the use of DA encapsulated within poly-
meric nanoparticles (93). DA-loaded NPs were prepared with copolymer PLGA by means 
of the double emulsion solvent evaporation method. This formulation was evaluated in a 
6-OHDA-induced rat model of PD, being able to successfully release the drug in the 
 striatum. Systemic i.v. administration of DA-loaded NPs caused a significant increase of DA 
levels and its metabolites and a reduction of DA-D2 receptor supersensitivity in the  striatum 
of parkinsonian rats. Moreover, the formulation significantly recovered neurobehavioral 
changes induced by 6-OHDA without causing any additional production of ROS, dopa-
minergic neuron degeneration, and structural changes in the striatum and SNpc when 
compared to 6-OHDA-lesioned rats.
Nowadays, L-DOPA is still considered the most effective drug in the treatment of PD. 
However, chronic administration of this agent usually results in L-DOPA-induced dyski-
nesia (LID), which has been related to its peak plasma concentration (94). To avoid this, Ren 
et al. (95) developed L-DOPA/benserazide-loaded PLGA microparticles which were admini-
stered to Sprague-Dawley rats in which PD was induced by stereotactic administration of 
6-OHDA. Subcutaneous administration of the microparticulate formulation improved 
motor function and ameliorated the expression of L-DOPA-induced dyskinesia (LID).
As previously indicated, ropinirole (RP), a dopamine agonist, stimulates striatal DA 
receptors being effective both as monotherapy and in combination therapy with levodopa. 
However, RP has low oral bioavailability and short elimination half-life which results in 
frequent dosing. Continuous delivery of RP from a transdermal system may avoid these 
drawbacks and help prevent or delay the onset of L-DOPA-related motor complications 
due to continuous dopaminergic stimulation. In this regard, Azeem et al. (96) developed a 
nanoemulsion gel for RP transdermal delivery. The new formulation was evaluated in a 
PD animal model induced in Wistar rats after stereotaxic administration of 10 mg 6-OHDA 
in 2 μL of 0.1 % in ascorbic acid-saline. The efficacy of the nanoemulsion was tested by 
analyzing three biochemical markers of oxidative stress (glutathione antioxidant enzymes, 
thiobarbituric acid reactive substances and catalase activity) with the results demonstrat-
ing that the new formulation was able to effectively restore the biochemical changes 
 induced by 6-OHDA.
Rotigotine (Ro) is a non-ergoline agonist of DA D3/D2/D1 receptors indicated for the 
treatment of both early and advanced PD. Giladi et al. (97), developed a transdermal patch 
for early PD that delivered the drug in patients at a constant rate for 24 h providing con-
tinuous plasma concentrations. However, there are some important side-effects related to 
the use of skin patches such as variability in the absorption rates from different skin areas 
and possible irritation after long-term application of the transdermal device (98). As PD 
patients require long-term treatments it would be interesting to develop a sustained- 
- release preparation of Ro to achieve continuous dopaminergic stimulation for long periods 
of time. For this purpose, Wang et al. (99), encapsulated Ro within PLGA microparticles 
(RoMPs) by an oil-in-water emulsion solvent evaporation technique and evaluated the de-
livery system in 6-OHDA-lesioned Sprague-Dawley rats (4 μg μL–1 6-OHDA in 0.9 % saline, 
containing 0.04 % ascorbic acid) in comparison with pulsatile L-DOPA administration. The 
pharmacokinetic study performed after intramuscular administration of RoMPs showed 
high and stable plasma and striatal drug levels for up to two weeks. Moreover, the micro-
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particulate Ro formulation exhibited steady efficacy which lasted for 2 weeks without any 
significant differences found between RoMPs treatment and pulsatile L-DOPA.
Tsai et al. (100) encapsulated apomorphine, a DA receptor agonist, in solid lipid 
nanoparticles (SLNs) in order to improve its very low oral bioavailability (< 2 %). The brain 
regional distribution of the nanoparticles was also evaluated. For this, pharmacokinetic 
studies were carried out in rats. Drug bioavailability was increased with NPs in respect to 
a reference solution. Apomorphine distribution in the striatum, the predominant site of its 
therapeutic action, also increased when using the solid-lipid nanoparticles (SLN). The 
anti-parkinsonian activity of apomorphine was evaluated in rats with 6-OHDA induced 
lesions. Animals treated with orally administered SLNs presented a significant improve-
ment when compared to those treated with the drug formulated in solution.
Glial cell line-derived neurotrophic factor (GDNF) is studied for the treatment of 
neuro degenerative disorders of basal ganglia origin such as PD. Garbayo et al. (101) investi-
gated the neurorestorative effects of controlled GDNF delivery when given as GDNF-loaded 
PLGA microparticles, which were prepared by a solvent extraction/evaporation method. 
The new delivery system was assessed in Sprague-Dawley rats that previously were stereo-
taxically injected with a total dose of 20 μg 6-OHDA dissolved in 10 μL of saline with 0.1 % 
ascorbic acid. The results demonstrated the efficacy of GDNF-loaded PLGA microparticles 
which resulted in a consistent improvement in behavior 6 weeks after stereotaxic injection 
of the delivery system. Moreover, 60 % of the animals treated with new formulation fully 
recovered from their rotational asymmetry 8 weeks after treatment, a response that was 
accompanied by a higher fiber density in the GDNF treated striatum.
Regarding lipid-based nanocarriers, Yang et al. (102) developed basic fibroblast growth 
factor (bFGF)-loaded liposomes for intranasal administration due to the neuroprotective 
effects of bFGF. The liposomal formulation was evaluated in a PD model induced in rats 
by 6-OHDA administration. The authors demonstrated that the new liposomal formula-
tion was able to deliver bFGF to the striatum and SNPc of rats and enhanced the neuropro-
tective effects of bFGF on dopaminergic neurons. Moreover, the bFGF liposomal formula-
tion markedly improved the behavioral alterations induced by 6-OHDA, increased the 
number of Nissl bodies, and ameliorated the loss of tyrosine hydroxylase (TH)-positive 
neurons.
Zhao et al. (103) formulated bFGF in phospholipid-based gelatin nanoparticles des-
tined to target the CNS also via intranasal administration. Hemi-parkinsonism was genera-
ted in rats by stereotaxic injection of 10 μL 6-OHDA solution in the right-side striatum. 
After administration, the integrity of the nasal mucosa was not affected. The results  obtained 
showed that bFGF not only stimulated dopaminergic function in surviving synapses but 
also played a neuroprotective effect.
In another approach, vascular endothelial growth factor (VEGF), a potent angiogenic 
factor with survival effects in neuronal cultures, was microencapsulated either alone or in 
combination with GDNF (104), in order to evaluate the efficacy of the formulation in the 
advanced stages of PD. For this, Sprague-Dawley rats were injected with 6-OHDA (7.5 and 
6 μg at two coordinates) to establish the PD model. The results showed that treatment with 
GDNF microspheres and with both VEGF and GDNF microspheres improved the rotation 
behavioral test, and resulted in higher levels of neurorepair and neuroregeneration.
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Table II summarizes the characteristics of the pesticide and neurotoxin-induced 
 animal models of PD. Finally, Table III summarizes different controlled-release systems 
developed for the treatment of PD and evaluated with pesticide or neurotoxin-induced 
animal models of PD.
CONCLUSIONS
Several animal models of PD are currently being used to help understanding the 
pathogenesis of this neurogenerative disorder as well as to evaluate the potential of new 
treatments developed for the disease. Some of these models are based on the use of neuro-
toxins in which substantial nigrostriatal degeneration is generally developed, as well as 
motor symptoms resembling those occurring in human PD. Regarding the development 
and evaluation of new drug delivery systems for PD, 6-OHDA is the one most frequently 
used. Although it needs to be injected intracerebrally, it exerts great selectivity of damage 
facilitating damage assessment. In addition, the scientific evidence on this neurotoxin is 
very extensive. MPTP is another neurotoxin frequently used. Unlike 6-OHDA, MPTP has 
the ability to cross the BBB, thereby facilitating its administration. Its mechanism of action 
has been extensively studied, with the MPTP-monkey model being considered the gold 
standard for preclinical testing of new therapeutic approaches for PD. However, the lack 
of facilities and expertise of researchers with monkey models is one of its main drawbacks.
Regarding pesticide-based animal models of PD, the agents usually employed are 
rotenone, paraquat and maneb. Systemic administration of rotenone mainly targets mito-
chondrial structures thereby triggering oxidative stress causing apoptosis of the dopami-
nergic neurons of the SNpc. Moreover, the rotenone rat model can cause the formation of 
α-synuclein inclusions as well as motor deficits resembling those occurring in PD. Para-
quat is also thought to cause dopaminergic degeneration by inducing oxidative stress, 
however, after chronic administration, this agent is not able to produce dopamine deple-
tion in the striatum or clear motor deficits.
From this review, it has been found that when evaluating new drug delivery systems 
developed for PD, 6-OHDA and rotenone are the most frequently used agents. However, 
there is still a need for further research since none of the animal models based either on 
the use of neurotoxins or pesticides can exactly mimic the neuropathological features 
 occurring in human PD.
Abbreviations, acronyms, symbols. – 6-OHDA – 6-hydroxydopamine, bFGF – basic fibroblast growth 
factor, COMT – catechol-O-methyltransferase, CPNPs – curcumin and piperine co-loaded glyceryl 
mono oleate NPs, DA – dopamine, DARC – detection apoptosing retinal cells, DAT – dopamine trans-
porter, GDNF – glial cell line-derived neurotrophic factor, GFAP – glial fibrillary acidic protein, LID – 
L-DOPA-induced dyskinesia, JNK – Jun N-terminal kinase, MAO-B – monoamine oxidase B, MB 
– maneb, ME – microemulsion, MEG – ME-based gel, MPP+ – 1-methyl-4-phenylpyridinium, MPs – 
microparticles, MPTP – 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, NDUFS4 – NADH dehydro-
genase ubiquinone proteins Fe-S4, NMDA – N-methyl-D-aspartate, NPs – nanoparticles, OCT – optical 
coherence tomography, PD – Parkinson’s disease, PLGA – poly(lactic-co-glycolic) acid, PPE-A – protein 
preproenkephalin-A, PQ – paraquat (1,1’-dimethyl-4,4’-bipyridyl dichloride), RM – rasagiline mesylate, 
RG – rosiglitazone, Ro – rotigotine, RoMPs – rotigotine microparticles, RP – ropinirole, RSV – resvera-
trol, RT – rotenone, SLNs – solid lipid nanoparticles, SNpc – substantia nigra pars compacta, TH – tyrosine 
hydroxylase, VEGF – vascular endothelial growth factor, α-Syn – alpha-synuclein
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